Rohit Aggarwal
Overview
Explore the profile of Rohit Aggarwal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
217
Citations
3983
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aggarwal A, Almackenzie M, Aggarwal R
J Rheumatol
. 2025 Mar;
PMID: 40089299
Idiopathic inflammatory myopathies (IIMs) comprise a spectrum of autoinflammatory disease characterized primarily by muscle inflammation, with secondary involvement of diverse organs including joints, skin, lungs, heart, and the gastrointestinal system....
2.
Bishnoi A, Tang I, Yoshida A, Pais F, Usman S, Dominguez S, et al.
Clin Exp Rheumatol
. 2025 Feb;
43(2):202-210.
PMID: 39977016
Idiopathic inflammatory myopathies (IIM), or myositis, are a heterogeneous group of systemic autoimmune disorders that are associated with significant morbidity and mortality. Conducting high-quality clinical trials in IIM is challenging...
3.
Charles-Schoeman C, Schessl J, Bata-Csorgo Z, Dimachkie M, Griger Z, Moiseev S, et al.
Rheumatology (Oxford)
. 2025 Feb;
PMID: 39918968
Objectives: The phase 3 ProDERM study demonstrated intravenous immunoglobulin (IVIg) was safe and effective in patients with dermatomyositis (DM). This analysis assessed clinical and serological predictors of IVIg response in...
4.
Fiorentino D, Mangold A, Werth V, Christopher-Stine L, Femia A, Chu M, et al.
Lancet
. 2025 Jan;
405(10473):137-146.
PMID: 39798982
Background: Dermatomyositis is a chronic autoimmune disease with distinctive cutaneous eruptions and muscle weakness, and the pathophysiology is characterised by type I interferon (IFN) dysregulation. This study aims to assess...
5.
Aggarwal R, Lundberg I, Song Y, Shaibani A, Werth V, Maldonado M
Arthritis Rheumatol
. 2024 Nov;
PMID: 39609094
Objective: Our objective was to evaluate the efficacy and safety of subcutaneous (SC) abatacept and standard of care (SOC) for the treatment of idiopathic inflammatory myopathy (IIM) over 52 weeks....
6.
Bae S, Abtin F, Kim G, Markovic D, Chan C, Moghadam-Kia S, et al.
RMD Open
. 2024 Nov;
10(4).
PMID: 39608864
Objectives: To explore the association between the extent of CT abnormalities by quantitative imaging analysis (QIA) and clinical/physiological disease parameters in patients with antisynthetase syndrome associated interstitial lung disease (ARS-ILD)....
7.
Aggarwal R, Oddis C, Sullivan D, Moghadam-Kia S, Saygin D, Kass D, et al.
BMC Pulm Med
. 2024 Oct;
24(1):544.
PMID: 39478532
Background: The Myositis Interstitial Lung Disease Nintedanib Trial (MINT) is a hybrid trial, which is enrolling patients both at local sites and remotely via a decentralised site. The trial will...
8.
Faghihi-Kashani S, Yoshida A, Bozan F, Zanframundo G, Rozza D, Loganathan A, et al.
Arthritis Rheumatol
. 2024 Oct;
PMID: 39467037
Objective: Anti-synthetase syndrome (ASSD) is a rare systemic autoimmune rheumatic disease (SARD) with significant heterogeneity and no shared classification criteria. We aimed to identify clinical and serological features associated with...
9.
Ambrocio K, Aggarwal R, Lacomis D, Zhang X, Garand K
Am J Speech Lang Pathol
. 2024 Oct;
33(6):2793-2804.
PMID: 39392897
Purpose: Evidence surrounding swallowing impairment in sporadic inclusion body myositis (IBM) is based on nonstandardized and nonvalidated assessment methods. We investigated (a) IBM's impact on swallowing function and oral intake...
10.
Aggarwal A, Bagri N, Kavadichanda C, Upadhyaya S, Haldule S, Ladha P, et al.
Int J Rheum Dis
. 2024 Sep;
27(9):e15351.
PMID: 39304342
No abstract available.